 Aridis Pharmaceuticals Inc NASDAQ: ARDS stock is surging after announcing encouraging preclinical data for pan coronavirus fully human monoclonal antibody mAb cocktail AR-701. The data show that the antibody is broadly reactive against the omicron and other COVID-19 variants, SARS Severe Acute Respiratory Syndrome, MERS Middle East Respiratory Syndrome Coronavirus, and seasonal common cold human coronaviruses. 